Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biolinerx Ltd ADR (BLRX)

Biolinerx Ltd ADR (BLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,791
  • Shares Outstanding, K 4,351
  • Annual Sales, $ 1,180 K
  • Annual Income, $ -1,180 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.31
  • Price/Sales 8.74
  • Price/Cash Flow N/A
  • Price/Book 0.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate $-0.50
  • Number of Estimates 1
  • High Estimate $-0.50
  • Low Estimate $-0.50
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +1.07%
on 03/30/26
3.02 -24.70%
on 03/02/26
-0.56 (-19.64%)
since 02/27/26
3-Month
2.25 +1.07%
on 03/30/26
3.20 -28.93%
on 02/09/26
-0.63 (-21.58%)
since 12/26/25
52-Week
2.25 +1.07%
on 03/30/26
7.77 -70.73%
on 05/30/25
-0.78 (-25.44%)
since 03/28/25

Most Recent Stories

More News
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma  and other cancers  

BLRX : 2.27 (+1.07%)
BioLineRx Reports 2025 Financial Results and Provides Corporate Update

- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -

BLRX : 2.27 (+1.07%)
BioLineRx to Report 2025 Annual Results on March 23, 2026

Management to Hold Conference Call at 8:30 a.m. EDT

BLRX : 2.27 (+1.07%)
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -

BLRX : 2.27 (+1.07%)
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Management to Hold Conference Call at 8:30 a.m. EST

BLRX : 2.27 (+1.07%)
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers)

BLRX : 2.27 (+1.07%)
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only -

BLRX : 2.27 (+1.07%)
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 - - Provides updated and extended...

BLRX : 2.27 (+1.07%)
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Management to Hold Conference Call at 8:30 a.m. EDT

BLRX : 2.27 (+1.07%)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 0.8569 (+6.45%)
IMRX : 5.27 (+7.99%)
CADL : 4.92 (+9.82%)
ONC.TO : 1.42 (+2.16%)
BLRX : 2.27 (+1.07%)

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

3rd Resistance Point 2.50
2nd Resistance Point 2.45
1st Resistance Point 2.35
Last Price 2.27
1st Support Level 2.20
2nd Support Level 2.15
3rd Support Level 2.05

See More

52-Week High 7.77
Fibonacci 61.8% 5.66
Fibonacci 50% 5.01
Fibonacci 38.2% 4.36
Last Price 2.27
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.